Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions.

Published in: British journal of clinical pharmacology (2022)

No connection between ARB pharmacology and their suspected ADRs could be found. No conclusion between sartan batch contaminations and increased suspected cancer-related ADRs was found.

Keyphrases

angiotensin ii
adverse drug
angiotensin converting enzyme
pulmonary embolism
vascular smooth muscle cells
risk assessment
emergency department
drinking water
climate change